指南与共识妇科生殖医学

国际循证指南:多囊卵巢综合征评估与管理的推荐意见

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
指南 / 共识 · Fertil Steril · 2018-07-19

该国际循证指南由多学科专家和患者共同参与制定,遵循AGREE II流程并采用GRADE框架,共形成166条推荐与实践要点,覆盖60个优先临床问题,旨在促进多囊卵巢综合征(PCOS)评估与管理的一致性和循证照护。

要点

  • 指南提供31条循证推荐、59条临床共识推荐和76条临床实践要点。
  • 关键变化包括细化个体诊断标准以提高诊断准确性、减少不必要检测。
  • 指南强调教育、生活方式干预、情绪健康与生活质量,以及更便宜安全的生育管理。

核心结论

  • 国际循证指南为PCOS的评估与管理提供基于最佳证据、多学科专家意见和患者偏好的明确建议。
  • 指南总体证据质量多为低至中等,需在這一被忽视但常见的疾病中开展更多研究,尤其围绕细化PCOS特定诊断特征。

研究设计与样本

  • 国际循证指南制定过程涉及专业学会和患者组织,多学科专家与PCOS女性全程直接参与。
  • 遵循AGREE II合规流程并进行广泛证据合成,采用GRADE框架评估证据质量、可行性、可接受性、成本、实施和推荐强度。
  • 治理结构包括六大洲国际顾问委员会、项目委员会、五个指南制定小组以及患者与转化委员会。
  • 37个学会和组织覆盖71个国家参与,15个月内召开20次面对面会议,解决60个优先临床问题,涉及40项系统评价和20项叙述性综述。
  • 推荐意见经五个指南小组共识投票制定和批准,根据国际反馈和同行评议修改,最终推荐经所有小组批准。

主要发现

  • PCOS评估与管理的证据质量总体为低至中等。
  • 指南提供31条循证推荐、59条临床共识推荐和76条临床实践要点,均与PCOS评估和管理相关。
  • 关键变化包括:个体诊断标准大幅细化以提高诊断准确性;减少不必要的检测;更加关注教育、生活方式调整、情绪健康和生活质量;强调循证药物治疗以及更便宜和更安全的生育管理。

关键数值与推荐

  • 指南共包含166条推荐和实践要点,涉及60个优先临床问题。
  • 证据质量总体为低至中等。

临床怎么用

  • 指南为临床医生提供基于最佳可用证据、多学科专家意见和患者偏好的明确最佳实践建议。
  • 指南制定了研究建议,并有全面的多层面传播与转化项目及 integrated evaluation program 支持指南实施。

局限性

  • 总体证据质量多为低至中等,需要在這一被忽视但常见的疾病中开展显著更多研究,尤其围绕细化PCOS特定诊断特征。
  • 承认区域卫生系统存在差异,并提供了指南和转化资源适应性调整的流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? SUMMARY ANSWER: International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. WHAT IS KNOWN ALREADY: Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. STUDY DESIGN, SIZE, DURATION: International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. PARTICIPANTS/MATERIALS, SETTING, METHODS: Governance included a six continent international advisory and a project board, five guideline development groups, and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. MAIN RESULTS AND THE ROLE OF CHANCE: The evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: i) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; ii) reducing unnecessary testing; iii) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and iv) emphasizing evidence based medical therapy and cheaper and safer fertility management. LIMITATIONS, REASONS FOR CAUTION: Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided. WIDER IMPLICATIONS OF THE FINDINGS: The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program. STUDY FUNDING/COMPETING INTEREST(S): The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine. Guideline development group members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Full details of conflicts declared across the guideline development groups are available at https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline in the Register of disclosures of interest. Of named authors, Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Laven declared grants from Ferring, Euroscreen and personal fees from Ferring, Euroscreen, Danone and Titus Healthcare. Prof. Norman has declared a minor shareholder interest in an IVF unit. The remaining authors have no conflicts of interest to declare. The guideline was peer reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREEII criteria and underwent methodological review. This guideline was approved by all members of the guideline development groups and was submitted for final approval by the NHMRC.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018. PMID: 30033227. doi:10.1016/j.fertnstert.2018.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。